D13S319
13q14. 
Combinations of multiplexed-FISH probes were ascribed to each individual tumor and its associated PDX based upon the cytogenetic aberrations initially detected by standard single probe FISH. Note: TTFT indicates time to first treatment; mo, months; PFS, progression-free survival; NT, not treated; ; Clb, chlorambucil; FC(R), fludarabine cyclophosphamide (rituximab); Flu, fludarabine; IbR, ibrutinib with rituximab; CR, complete response; PR, partial response; b alive at time of censor; del, deletion of part of chromosome specified; +12, trisomy 12; .R, red; G, green; A, aqua; Y, yellow. CLL20 was generated in 6 NOG mice. Engraftment was confirmed by flow cytometry and mice were randomised into treatment or control groups. Mice were treated with fludarabine/cyclophosphamide (FC; 0.625mg/kg and 6.25mg/kg, respectively) or vehicle three times per week for two weeks. CLL cells were isolated from spleens by FACS and cytogenetic subpopulations determined by multiplexed-FISH. The subclonal representation of the different cytogenetic subpopulations comparing the two treatment groups is depicted. 11q-indicates del(11q); 13q-: del(13q); del 13q-/-: del(13q)x2. Statistical significance denoted by *P<0.05. Error bars represent SEM.
